II.2.3) Place of performance
NUTS code:
UKC
UKD
UKE
UKF
UKG
UKH
UKI
UKJ
UKK
II.2.4) Description of the procurement
This service will serve Service Users aged 18 and over registered with a Dorset GP practice who comply with the thresholds contained within the Evidence Based Intervention Policy for Specialist Weight Management Services.
Service
• All Service Users must be eligible and currently prescribed the approved treatment option (tirzepatide) in this service.
• All Service Users will have a documented individualised treatment that recognises any co-morbidities and personalisation of care.
• All Service users will be offered a range of appointments, including face-to-face, group or digital appointments.
• All service users will be offered appointments at various times, including evening and weekends.
• All service users not qualifying for ongoing weight loss medication must be signposted to alternative support in line with the weight management pathway in Appendix A and discharged from the service.
Outcome Measures
• 75% of service users will report an improvement in physical and mental well-being, as measured by a standardised quality of life scores within 12 weeks of joining the programme.
• 75% of service users will report adoption of sustainable healthy eating habits, regular physical activity, and positive behavioural changes within 12 weeks of joining the programme.
First 72 weeks
• All service users must have a quarterly review after reaching maximum tolerated dose of medication.
• All service users must engage with local or nationally commissioned wraparound services that support psychological, calorie restriction and exercise as specified while being prescribed the weight-loss medication otherwise it should be withdrawn.
• 95% of service users should continue to attend follow-up appointments and maintain a body weight reduction of 15% at 72 weeks dependent on the dose of medicine prescribed .
• 90% reduction in the risk of progression to type 2 diabetes for all service users.
Maintenance after 72 weeks
• 95% of all service users must continue to lose or maintain minimum 15% from baseline weight loss over a period of three years.
• Diversion of medicines will result in service users being declined further pharmacological therapy.
• Where weight loss targets are maintained and engagement with follow-up and wraparound services completed, service users may be prescribed therapy for the 3-year initial treatment on advice from their healthcare professional prior to evaluation of the service by NHS England or replacement body.
II.2.5) Award criteria
Cost criterion: Technical & Quality
/ Weighting: 70%
Cost criterion: Social Value
/ Weighting: 10%
Cost criterion: Price
/ Weighting: 20%
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No